Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 829 citations · Adam Yopp
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Lancet (London, England) · 2023 · 469 citations · Adam Yopp
Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI.
Nature medicine · 2022 · 467 citations · Mudathir Ibrahim
Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI.
BMJ (Clinical research ed.) · 2022 · 317 citations · Mudathir Ibrahim
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.
Cancer discovery · 2021 · 515 citations · Prasad Adusumilli
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
Nature communications · 2021 · 385 citations ·
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
Journal of the National Comprehensive Cancer Network : JNCCN · 2023 · 191 citations · Adam Yopp
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · 64 citations · Adam Yopp